Biogen Financials

BIIB34 Stock  BRL 152.10  1.58  1.05%   
We suggest to use Biogen Inc fundamental analysis to see if markets are presently undervaluing or overvaluing the company. Put another way, you can use it to find out if Biogen Inc is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to collect and analyze data for twenty-nine available fundamental indicators for Biogen Inc, which can be compared to its peers. The stock experiences a large bullish trend. Check odds of Biogen to be traded at R$167.31 in 90 days.
  
Understanding current and past Biogen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biogen's financial statements are interrelated, with each one affecting the others. For example, an increase in Biogen's assets may result in an increase in income on the income statement.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.

Biogen Stock Summary

Biogen competes with British American, Capital One, Metalurgica Gerdau, Deutsche Bank, and Discover Financial. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 7800 people.
InstrumentBrazil Stock View All
ExchangeSao Paulo Exchange
Business Address225 Binney Street,
SectorHealthcare
IndustryDrug Manufacturers - Major
BenchmarkDow Jones Industrial
Websitewww.biogen.com
Phone617 679 2000
CurrencyBRL - Brazilian Real
You should never invest in Biogen without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biogen Stock, because this is throwing your money away. Analyzing the key information contained in Biogen's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Biogen Key Financial Ratios

Biogen's financial ratios allow both analysts and investors to convert raw data from Biogen's financial statements into concise, actionable information that can be used to evaluate the performance of Biogen over time and compare it to other companies across industries.

Biogen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biogen's current stock value. Our valuation model uses many indicators to compare Biogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biogen competition to find correlations between indicators driving Biogen's intrinsic value. More Info.
Biogen Inc is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about  0.38  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biogen Inc is roughly  2.66 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biogen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biogen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Biogen Inc Systematic Risk

Biogen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biogen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Biogen Inc correlated with the market. If Beta is less than 0 Biogen generally moves in the opposite direction as compared to the market. If Biogen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biogen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biogen is generally in the same direction as the market. If Beta > 1 Biogen moves generally in the same direction as, but more than the movement of the benchmark.

Biogen January 11, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Biogen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biogen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biogen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Biogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biogen's daily price indicators and compare them against related drivers.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets